Diabetes drug shows promise in fighting lethal cancer co... (st that same tendency toward insulin res...)

Diabetes drug shows promise in fighting lethal cancer complication

Date:9/24/2009

st that same tendency toward insulin resistance.

The scientists injected mice with colon cancer cells to mimic one of several digestive-system cancers strongly associated with the development of cachexia. Less than two weeks after the cancer started growing, these mice had become insulin resistant. Control mice without tumors had normal insulin sensitivity. Insulin resistance means that the presence of insulin does not initiate the transfer of sugar, or glucose, from the blood into the tissues, where it is used for energy.

Just three days later, the mice with cancer weighed, on average, 20 percent less than control mice with no tumors; weight loss of at least 5 percent is considered to be a sign of cachexia in humans. By day 19, the total muscle weight in mice with cancer decreased by 29 percent and the weight of their fat tissue dropped by 73 percent. Such rapid loss of muscle and fat indicated these mice had indeed developed cachexia.

"These data provide evidence that in mice with colon cancer tumors, insulin resistance may be involved in the development of cachexia rather than occur as a result of cachexia," Belury said. "And the key here is that people and animals with cachexia do not want to be losing weight. They can eat more and it doesn't matter. There's something internally that's driving this fat and muscle loss."

In the second study, the scientists tested whether rosiglitazone could "rescue" the insulin resistance in mice with colon cancer.

In this study, mice were fed a high-fat diet and randomized into three groups: mice with and without tumors receiving a saline solution as a control, and mice with tumors treated with daily injections of rosiglitazone.

Within eight days, the mice with cancer receiving the rosiglitazone showed more sensitivity to insulin than did the mice with tumors that received no medication. The insulin sensitivity of the medicated mice matched that of mice without tumors.

Contact: Martha Belury
belury.1@osu.edu
614-292-1680
Ohio State University
Source:Eurekalert

2

GOOD

Page: 1 2 3
Related biology news :

1. 1 million euro EU grant for MDC diabetes researcher Dr. Francesca M. Spagnoli
2. Diabetes drug kills cancer stem cells in combination treatment in mice
3. Size of fat cells and waist size predict type 2 diabetes in women
4. Medicine wheel model for nutrition shows promise for control of type 2 diabetes
5. JDRF-funded studies show regular CGM use increases diabetes control for all age groups
6. Scientists discover new genetic variation that contributes to diabetes
7. Diabetes advance: Researchers find gene that causes resistance to insulin
8. DNA mutations linked to diabetes
9. UCF discovery could open door to obesity, diabetes treatments
10. Stimulus funding helps K-State biochemist study eyes lens in diabetes, galactosemia patients
11. Common allergy drug reduces obesity and diabetes in mice

Post Your Comments:

(Date:12/16/2009)... of Energy Steven Chu announced today the winners of ... in research and development supporting the Department of Energy ... will receive a gold medal, a citation and $50,000. ... in Washington, DC early next year., "The contributions made ... energy security of the United States are wide-ranging and ...

(Date:12/16/2009)... that short-term, seasonal exposure to pesticides in rivers ... of wild salmon populations. In addition to the ... that exposure to commonly used pesticides may further ... , "Major efforts are currently underway to ... recover depressed populations," says David Baldwin of the ...

(Date:12/16/2009)... 1 GestureTek Inc. today announced ... - a turnkey, portable, plug and play ... entertainment and touring promotions. GestureTek is the ... in camera-enabled gesture recognition technology for interactive ... for quality, the CUBE has TUV, CE, ...

Breaking Biology News(10 mins):Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners 2 Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3 Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 1 Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 2 Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 3 Hispanic children in US at greater risk for obesity than other ethnic racial groups 47469 1 Hispanic children in US at greater risk for obesity than other ethnic racial groups 47469 2 Is your environment damaging your health 3F New center aims to find out 47466 1 Is your environment damaging your health 3F New center aims to find out 47466 2 Is your environment damaging your health 3F New center aims to find out 47466 3

[0] Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners [0] Even at sublethal levels, pesticides may slow the recovery of wild salmon populations [0] GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits

... Spearhead Effort in Support of "New Employee,Verification Act", ... largest,association devoted to human resource management today led ... endorse the "New Employee,Verification Act." In testimony today ... Security, Sue Meisinger, President and CEO of SHRM,urged ...

... A better understanding of brain injury, a way to ... to monitor their glaucoma at home, number among this ... day. , What surprises me every time I walk ... projects involving so many NJIT graduate and undergraduate students, ...

... . , A new brain-imaging study by researchers ... - a stomach hormone, acts on specific regions of the ... eating for pleasure. This study, published in the May ... and treating obesity, a condition affecting millions world-wide. , Appetite ...

Other Biology News:SHRM CEO Testifies Before House Subcommittee on Social Security 2 SHRM CEO Testifies Before House Subcommittee on Social Security 3 NJIT applauds students for studies on brain injury, glaucoma and more 2 Hunger hormone: Makes food more attractive 2

SHRM CEO Testifies Before House Subcommittee on Social Security NJIT applauds students for studies on brain injury, glaucoma and more Hunger hormone: Makes food more attractive

(Date:12/16/2009)... Special Protocol Assessment with the Food and ... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on oncology and ... its partner Keryx Biopharmaceuticals Inc. ("Keryx") ( ... trial for perifosine (KRX-0401), the Company,s PI3K/Akt ...

(Date:12/16/2009)... Peptone. HSP A has been found to be effectinve in ... ... 16, 2009 -- Nu-Tek BioSciences, LLC. ( www.nu-tekproducts.com ) is meeting ... HSP-A, previously manufactured by Nutricepts, Inc. (Burnsville, Mn), is a high ... and yields. HSP-A has been found to be especially effective ...

(Date:12/15/2009)... Joint BioEnergy Institute (JBEI), one of three Department of ... trusted time-stamping service to protect its valuable intellectual property. ... ... VA (PRWEB) December 15, 2009 -- Surety, LLC ... solutions , today announced that the Joint BioEnergy Institute ...

(Date:12/15/2009)... NEW YORK, Dec. 15 Reportlinker.com ... is available in its catalogue: ,, ... - Market Forecasts to 2015, Pipeline Analysis ... http://www.reportlinker.com/p0168104/The-Future-of-Orphan-Diseases-Therapeutics---Market-Forecasts-to-2015-Pipeline-Analysis-and-Reimbursement.html ,, Summary ... latest research "The Future of Orphan Diseases ...

[0] AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma [0] Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone [0] Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement

... Mezzanine Debt Facility; Support Profitable GrowthALISO VIEJO, Calif., May ... CLRT ), a premier anatomic pathology and ... pharmaceutical industry, announced today that it has completed the ... stock with Oak Investment Partners , ...

... The Institut Pasteur and Merieux Alliance,have signed a letter ... The Institut Pasteur and Merieux Alliance ... Silliker) would like to,pool their resources and efforts to ... fields: , , - Clinical diagnostics ...

... With Movement Disorders at Home and in a Variety ... people in the US have diseases or conditions that ... traditional walking aids such as canes and walkers are ... and live independently.Now there,s a high-tech yet easy-to-use gait-training ...

Other Biology Technology:Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 2 Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 3 Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 4 Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 5 Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 6 The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases 2 The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases 3 Now Available: State-of-the-Art Gait Training Device to Help Millions Walk More Normally Again 2

Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases Now Available: State-of-the-Art Gait Training Device to Help Millions Walk More Normally Again

Human DEP-1/CD148 Fluorescein MAb (Clone 143-41) Protein Family: Granulocyte Markers, Monocyte Markers, Phosphatases & Regulators, Other Dendritic Cell Molecules...

MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....

NNT-1/BSF-3 (N-14)...

Monoclonal 8C2.1 is specific for Bunyavirus G1 as tested by neutralization, immunoprecipitation and immunobinding assays....

Biology Products:

Mouse Anti-Human DEP-1 / CD148 Monoclonal Antibody, Fluorescein Conjugated, Clone 143-41 from R&D Systems Mouse Anti-Porcine SLA 1 Monoclonal Antibody, FITC Conjugated from AbD Serotec Goat Anti-NNT-1/BSF-3 (N-14) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.Anti-Bunyavirus (G1) Monoclonal Antibody, Unconjugated, Clone 8C2.1 from CHEMICON

Diabetes drug shows promise in fighting lethal cancer co...(st that same tendency toward insulin res...)